India Launches Pluvicto for Advanced Prostate Cancer Treatment
| Topic | Key Details |
|---|---|
| Therapy Name | Pluvicto (radioligand therapy) |
| Approval | First regulatory-approved radioligand therapy for advanced prostate cancer in India. |
| Developer | Novartis |
| Target Condition | PSMA-positive metastatic prostate cancer (cancer spread beyond prostate gland). |
| Mechanism | Combines targeting molecule with radioactive isotope Lutetium-177 to deliver radiation directly to cancer cells. |
| Advantage | Minimizes damage to healthy tissues (precision targeting). |
| Clinical Benefit | - Reduces risk of disease progression/death (Phase III trials). - Improves quality of life vs. standard treatments. |
| Prostate Cancer Stats (India) | - 250,000 cases annually. - Over 50% diagnosed at advanced stages. - Among top 3 cancers in urban Indian men. |
| Infrastructure | - 250+ nuclear medicine centers in India. - Requires specialized facilities for radioactive handling. |
| Availability | Initially imported from Novartis facilities (Spain/Italy); available at select hospitals. |
| Global Significance | Radioligand therapy is a growing field in precision oncology, with potential applications for other cancers. |